CAR-NK 细胞治疗血液肿瘤的研究进展
刘洪秀， 韩艳秋 - 临床血液学杂志, 2023 - lcxy.whuhzzs.com
NK 细胞作为固有免疫细胞在肿瘤免疫监视中发挥重要作用. 相比CAR-T 其神经毒性,
细胞因子释放综合征等不良反应和移植物抗宿主病鲜有发生, 因此有希望成为嵌合抗原受体细胞 …
细胞因子释放综合征等不良反应和移植物抗宿主病鲜有发生, 因此有希望成为嵌合抗原受体细胞 …
From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies
H Lu, X Zhao, Z Li, Y Hu, H Wang - Frontiers in Oncology, 2021 - frontiersin.org
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …
CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges
Adoptive cell treatment (ACT) utilizing chimeric antigen receptors (CAR) diverts the
specificity of safe cells against a target-specific antigen and portrays exceptional potential for …
specificity of safe cells against a target-specific antigen and portrays exceptional potential for …
Progress in chimeric antigen receptor NK cell therapy for hematological malignancies
XD Wang, H Mei, Y Hu - Zhonghua xue ye xue za zhi= Zhonghua …, 2022 - europepmc.org
近年来, 细胞治疗显现出巨大的研究潜力和临床价值. 嵌合抗原受体 T 细胞 (CAR-T 细胞)
治疗在血液肿瘤领域已取得重大进展, CD19 CAR-T 治疗 B-ALL 完全缓解率高达 90%[1]. 但 …
治疗在血液肿瘤领域已取得重大进展, CD19 CAR-T 治疗 B-ALL 完全缓解率高达 90%[1]. 但 …
CAR-NK cells in the treatment of solid tumors
E Wrona, M Borowiec, P Potemski - International journal of molecular …, 2021 - mdpi.com
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of
patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy …
patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy …
CAR-NK cells: a promising cellular immunotherapy in lymphoma
S Khanmohammadi, N Rezaei - Expert Opinion on Biological …, 2023 - Taylor & Francis
Introduction New methods in cancer immunotherapy, such as chimeric antigen receptor
(CAR)-T cells, have shown promising results in destroying malignant cells. However …
(CAR)-T cells, have shown promising results in destroying malignant cells. However …
Current progress of CAR-NK therapy in cancer treatment
Z Pang, Z Wang, F Li, C Feng, X Mu - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptor (CAR)-T and-natural killer (NK) therapies are
promising in cancer treatment. CAR-NK therapy gains great attention due to the lack of …
promising in cancer treatment. CAR-NK therapy gains great attention due to the lack of …
嵌合抗原受体NK 细胞在淋巴瘤治疗中的研究进展
胡润， 姚沛， 李俊蒽， 桂仁捷， 段华新 - 肿瘤防治研究, 2023 - zlfzyj.com
过继细胞治疗是近年来肿瘤研究的热点, 嵌合抗原受体T 细胞(CAR-T) 在血液肿瘤中已取得巨大
成功, 在一定程度上改变了目前肿瘤治疗格局, 然而CAR-T 疗法的严重不良反应及高昂的治疗 …
成功, 在一定程度上改变了目前肿瘤治疗格局, 然而CAR-T 疗法的严重不良反应及高昂的治疗 …
CAR-NK Cells: A Systematic Review of Emerging Alternative on Immunotherapy Against Leukemia
A Prasetya, R Soetedjo, E Saputra Arifin - Iranian Journal of Blood and …, 2022 - ijbc.ir
Background: Cancer is a public health emergency. It has a high mortality rate despite
numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer …
numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer …